PPP2R1B
Basic information
Region (hg38): 11:111726908-111766389
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PPP2R1B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 28 | 34 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 1 | |||||
Total | 0 | 0 | 28 | 7 | 1 |
Variants in PPP2R1B
This is a list of pathogenic ClinVar variants found in the PPP2R1B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-111726958-T-C | PPP2R1B-related disorder | Likely benign (Sep 17, 2019) | ||
11-111726969-T-A | PPP2R1B-related disorder | Likely benign (Jun 01, 2022) | ||
11-111727038-C-T | not specified | Likely benign (Jan 08, 2024) | ||
11-111727039-G-A | not specified | Uncertain significance (Feb 14, 2023) | ||
11-111737492-T-A | PPP2R1B-related disorder | Likely benign (Nov 01, 2022) | ||
11-111737534-C-G | PPP2R1B-related disorder | Benign (Nov 18, 2019) | ||
11-111742059-T-C | PPP2R1B-related disorder | Likely benign (Jul 20, 2022) | ||
11-111742068-G-C | not specified | Uncertain significance (Mar 16, 2022) | ||
11-111742079-T-C | not specified | Uncertain significance (May 07, 2024) | ||
11-111742515-A-C | PPP2R1B-related disorder | Likely benign (Jan 06, 2020) | ||
11-111742589-T-C | not specified | Uncertain significance (Jul 22, 2022) | ||
11-111742628-T-A | not specified | Uncertain significance (Aug 17, 2021) | ||
11-111742643-T-A | not specified | Uncertain significance (Jun 03, 2022) | ||
11-111743383-C-T | not specified | Uncertain significance (Nov 29, 2023) | ||
11-111743423-T-C | not specified | Uncertain significance (Nov 03, 2023) | ||
11-111743450-T-C | not specified | Uncertain significance (Jul 14, 2021) | ||
11-111743482-T-G | not specified | Uncertain significance (Jun 30, 2023) | ||
11-111743527-T-C | not specified | Uncertain significance (Sep 17, 2021) | ||
11-111752301-T-C | not specified | Uncertain significance (Aug 09, 2021) | ||
11-111752319-C-T | not specified | Uncertain significance (Jan 04, 2022) | ||
11-111752323-C-T | not specified | Uncertain significance (Oct 12, 2021) | ||
11-111753448-C-T | not specified | Uncertain significance (Mar 06, 2023) | ||
11-111753522-A-G | not specified | Uncertain significance (Jan 10, 2023) | ||
11-111753543-G-A | not specified | Uncertain significance (Aug 01, 2022) | ||
11-111754509-G-A | not specified | Uncertain significance (Jul 26, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PPP2R1B | protein_coding | protein_coding | ENST00000311129 | 16 | 39520 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.00e-15 | 0.239 | 125467 | 2 | 279 | 125748 | 0.00112 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.07 | 311 | 369 | 0.843 | 0.0000194 | 4323 |
Missense in Polyphen | 67 | 99.621 | 0.67255 | 1027 | ||
Synonymous | 0.589 | 125 | 134 | 0.935 | 0.00000665 | 1340 |
Loss of Function | 1.26 | 27 | 35.0 | 0.771 | 0.00000179 | 420 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00185 | 0.00185 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.000601 | 0.000554 |
European (Non-Finnish) | 0.00139 | 0.00136 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.00132 | 0.00131 |
Other | 0.00215 | 0.00196 |
dbNSFP
Source:
- Function
- FUNCTION: The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);TGF-beta signaling pathway - Homo sapiens (human);Dopaminergic synapse - Homo sapiens (human);Oocyte meiosis - Homo sapiens (human);Long-term depression - Homo sapiens (human);Tight junction - Homo sapiens (human);mRNA surveillance pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Adrenergic signaling in cardiomyocytes - Homo sapiens (human);Hippo signaling pathway - Homo sapiens (human);Chagas disease (American trypanosomiasis) - Homo sapiens (human);Sphingolipid signaling pathway - Homo sapiens (human);Hepatitis C - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;Wnt Signaling Pathway and Pluripotency;PI3K-Akt Signaling Pathway;Glycogen Metabolism;Signaling by GPCR;Degradation of beta-catenin by the destruction complex;RAF activation;Toll Like Receptor 7/8 (TLR7/8) Cascade;Interleukin-17 signaling;Signaling by WNT;Signal Transduction;Gene expression (Transcription);Inhibition of replication initiation of damaged DNA by RB1/E2F1;Signaling by Interleukins;Generic Transcription Pathway;Metabolism of carbohydrates;Cytokine Signaling in Immune system;Toll Like Receptor 9 (TLR9) Cascade;PP2A-mediated dephosphorylation of key metabolic factors;GPCR Dopamine D1like receptor;MyD88 cascade initiated on plasma membrane;Toll Like Receptor 10 (TLR10) Cascade;Toll Like Receptor 3 (TLR3) Cascade;Toll Like Receptor 5 (TLR5) Cascade;Toll-Like Receptors Cascades;CTLA4 inhibitory signaling;Costimulation by the CD28 family;MASTL Facilitates Mitotic Progression;RNA Polymerase II Transcription;Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal;Amplification of signal from the kinetochores;Mitotic Spindle Checkpoint;Cell Cycle Checkpoints;Innate Immune System;Immune System;Metabolism;Cyclin D associated events in G1;G1 Phase;Adaptive Immune System;insulin Mam;RHO GTPases Activate Formins;E2F mediated regulation of DNA replication;Mitotic G1-G1/S phases;Nuclear Events (kinase and transcription factor activation);Disassembly of the destruction complex and recruitment of AXIN to the membrane;Cyclin A/B1/B2 associated events during G2/M transition;DARPP-32 events;Glycolysis;RHO GTPase Effectors;Signaling by Rho GTPases;ERKs are inactivated;Signaling by NTRK1 (TRKA);Signaling by NTRKs;ERK/MAPK targets;MAPK targets/ Nuclear events mediated by MAP kinases;MAP kinase activation;TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;Hemostasis;MyD88 dependent cascade initiated on endosome;Negative regulation of MAPK pathway;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;Regulation of TP53 Degradation;Regulation of TP53 Expression and Degradation;G2/M Transition;Mitotic G2-G2/M phases;PIP3 activates AKT signaling;G1/S Transition;Beta-catenin phosphorylation cascade;Mitotic Prophase;Regulation of TP53 Activity;Transcriptional Regulation by TP53;PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling;Negative regulation of the PI3K/AKT network;Mitotic Prometaphase;Separation of Sister Chromatids;Mitotic Anaphase;Mitotic Metaphase and Anaphase;Opioid Signalling;G alpha (i) signalling events;M Phase;Glucose metabolism;Cell Cycle;Resolution of Sister Chromatid Cohesion;TRIF(TICAM1)-mediated TLR4 signaling ;MyD88-independent TLR4 cascade ;Toll Like Receptor 4 (TLR4) Cascade;Signaling by Receptor Tyrosine Kinases;Integration of energy metabolism;Platelet sensitization by LDL;Platelet homeostasis;Cell Cycle, Mitotic;GPCR downstream signalling;Intracellular signaling by second messengers;MyD88:Mal cascade initiated on plasma membrane;Toll Like Receptor TLR1:TLR2 Cascade;Toll Like Receptor TLR6:TLR2 Cascade;Toll Like Receptor 2 (TLR2) Cascade;TCF dependent signaling in response to WNT;insulin
(Consensus)
Recessive Scores
- pRec
- 0.108
Intolerance Scores
- loftool
- 0.491
- rvis_EVS
- 0.09
- rvis_percentile_EVS
- 60.57
Haploinsufficiency Scores
- pHI
- 0.891
- hipred
- Y
- hipred_score
- 0.624
- ghis
- 0.430
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.922
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ppp2r1b
- Phenotype
- hematopoietic system phenotype; reproductive system phenotype; immune system phenotype;
Gene ontology
- Biological process
- protein dephosphorylation;regulation of phosphoprotein phosphatase activity;apoptotic process involved in morphogenesis;positive regulation of extrinsic apoptotic signaling pathway in absence of ligand
- Cellular component
- protein phosphatase type 2A complex;cytoplasm;membrane raft;extracellular exosome
- Molecular function
- protein serine/threonine phosphatase activity;protein binding;protein phosphatase regulator activity